Henry Skinner is a microbiologist and venture investor who leads the AMR Action Fund, focusing on antimicrobial drug development challenges. He has held leadership roles in pharmaceuticals, biotech, and venture capital.
One email when Henry's firm raises a fund, adds a partner or shows new activity.

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.
Send your deckHenry Skinner is a microbiologist and venture investor who leads the AMR Action Fund, focusing on antimicrobial drug development challenges. He has held leadership roles in pharmaceuticals, biotech, and venture capital.
AMR Action Fund has not reported a check size.
A warm intro from a founder AMR Action Fund backed works best.
Deputy Head and Managing Director at Novartis Venture Fund; Senior Vice President, Venture at Tekla Capital Management; President and Chief Executive Officer at NeoGenesis Pharmaceuticals; Chief Executive Officer at SelectX Pharmaceuticals; Executive Director, Head Strategic Alliances at Novartis Institutes for Biomedical Research; Vice President and Deputy Head and Managing Director at Novartis Venture Fund; Senior Vice President of Venture at Tekla Capital Management.
Last updated 2026-10-15. Is this you? Ask for a correction.